Last updated on June 2018

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease


Brief description of study

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of elenbecestat (proposed international nonproprietary name [INN]) (E2609).

Clinical Study Identifier: NCT02956486

Contact Investigators or Research Sites near you

Start Over

Eisai Medical Information

Facility #1
Parkville, Australia
  Connect »

Eisai Medical Information

Facility #2
Melbourne, Australia
1.89miles
  Connect »

Eisai Medical Information

Facility #3
Melbourne, Australia
1.89miles
  Connect »

Eisai Medical Information

Facility #1
Malvern, Australia
6.65miles
  Connect »

Eisai Medical Information

Facility #1
Heidelberg, Australia
6.96miles
  Connect »

Eisai Medical Information

Facility #1
Caulfield, Australia
7.81miles
  Connect »